MDMadrigal Pharmaceuticals MDGL · NASDAQ
$437.74 +0.81% (+$3.50)
- Market cap
- $10.1B
- Enterprise value
- $10.2B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 7.9x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -37.0%
- Gross margin
- 91.5%
- Net margin
- -25.3%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- -1.05
- Free float
- 93.2%
About the company
Madrigal Pharmaceuticals, Inc. is an American biotechnology company focused on developing new therapeutic drugs for liver and cardiometabolic diseases. The company specializes in research and development of drugs aimed at improving liver health, particularly in relation to non-alcoholic steatohepatitis (NASH) and cirrhosis. Madrigal Pharmaceuticals is known for its innovative technology targeting selective activation of liver receptors, which has the potential to provide effective therapeutic options for patients suffering from these complex and difficult-to-treat conditions.
Sector
Healthcare
Industry
Biotechnology
CEO
William J. Sibold
Employees
915
Headquarters
West Conshohocken
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Analysts expect revenue to grow by 59% this fiscal year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What to watch: It passes only 2 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number